Login / Signup

The Quest for Oral PROTAC drugs: Evaluating the Weaknesses of the Screening Pipeline.

Giulia AppratoGiuseppe ErmondiGiulia Caron
Published in: ACS medicinal chemistry letters (2023)
A targeted bibliographic search exposed the deficiencies within existing PROTAC preclinical pipelines, including missing, poor-quality data and technical limitations in the experimental assays. Several recommendations are proposed to improve the efficiency of preclinical platforms for PROTACs.
Keyphrases
  • cell therapy
  • cancer therapy
  • clinical practice
  • quality improvement
  • stem cells
  • mesenchymal stem cells
  • artificial intelligence